Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Innovative herbicide discovery firm MoA Technology moves to TOSP

28 Jun 2021

Innovative herbicide discovery firm MoA Technology moves to TOSP Third occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, June 28 2021 – MoA Technology, which is focused on providing farmers with a diverse choice of innovative technologies for weed control, is the third occupier of the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The Oxford... Read more

ATDBio establishes molecular diagnostics lab to support customer research

21 Jun 2021

ATDBio establishes molecular diagnostics lab to support customer research Leading nucleic acid maker evolves activity & builds on pandemic experience Oxford, UK, June 21 2021 – ATDBio, a leading innovative manufacturer of synthetic DNA and RNA oligonucleotides, has established a new 745 sq ft molecular diagnostics research and quality control laboratory at The Oxford Science Park. Driven by its experience during the coronavirus... Read more

Exscientia acquires personalised medicine AI pioneer Allcyte

15 Jun 2021

Deep learning platform evaluates drug activity in patient tumour microenvironments with single cell resolution First AI platform clinically validated to improve treatment outcomes in prospective study Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The combination expands Exscientia’s translational capabilities by... Read more

OBN Announce the 2020 OBN Award winners

14 Jun 2021

We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. The Awards, which are in their 12th year, shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life... Read more

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease

08 Jun 2021

Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease Cytox genoSCORE-LAB test can identify patients most at risk of cognitive decline, and potentially most likely to benefit from new drug 8th June 2021: Oxford and Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer’s disease (AD) and dementia, welcomes the decision from the US FDA to... Read more

News